Literature DB >> 32722784

Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains.

Monica Sacco1, Stefano Lancellotti2, Mattia Ferrarese3, Francesco Bernardi3, Mirko Pinotti3, Maira Tardugno1, Erica De Candia1,2, Leonardo Di Gennaro2, Maria Basso2, Betti Giusti4,5, Massimiliano Papi6, Giordano Perini6, Giancarlo Castaman7, Raimondo De Cristofaro1,2.   

Abstract

We observed a 55-year-old Italian man who presented with mucosal and cutaneous bleeding. Results of his blood analysis showed low levels of von Willebrand factor (VWF) antigen and VWF activity (both VWF ristocetin cofactor and VWF collagen binding), mild thrombocytopenia, increased ristocetin-induced platelet aggregation, and a deficiency of high-molecular-weight multimers, all typical phenotypic hallmarks of type 2B von Willebrand disease (VWD). The analysis of the VWF gene sequence revealed heterozygous in cis mutations: (1) c.2771G>A and (2) c.6532G>T substitutions in the exons 21 and 37, respectively. The first mutation causes the substitution of an Arg residue with a Gln at position 924, in the D'D3 domain. The second mutation causes an Ala to Ser substitution at position 2178 in the D4 domain. The patient's daughter did not present the same fatherly mutations but showed only the heterozygous polymorphic c.3379C>T mutation in exon 25 of the VWF gene causing the p.P1127S substitution, inherited from her mother. The in vitro expression of the heterozygous in cis VWF mutant rVWFWT/rVWF924Q-2178S confirmed and recapitulated the ex vivo VWF findings. Molecular modeling showed that these in cis mutations stabilize a partially stretched and open conformation of the VWF monomer. Transmission electron microscopy and atomic force microscopy showed in the heterozygous recombinant form rVWFWT/rVWF924Q-2178S a stretched conformation, forming strings even under static conditions. Thus, the heterozygous in cis mutations 924Q/2178S promote conformational transitions in the VWF molecule, causing a type 2B-like VWD phenotype, despite the absence of typical mutations in the A1 domain of VWF.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32722784      PMCID: PMC7391138          DOI: 10.1182/bloodadvances.2020002334

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  55 in total

1.  The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. A clinical, biochemical and in silico study.

Authors:  Stefano Lancellotti; Flora Peyvandi; Maria Teresa Pagliari; Andrea Cairo; Safwat Abdel-Azeim; Edrisse Chermak; Ilaria Lazzareschi; Stefano Mastrangelo; Luigi Cavallo; Romina Oliva; Raimondo De Cristofaro
Journal:  Thromb Haemost       Date:  2015-08-13       Impact factor: 5.249

2.  Biophysical investigations of engineered polyproteins: implications for force data.

Authors:  Ross W S Rounsevell; Annette Steward; Jane Clarke
Journal:  Biophys J       Date:  2004-12-21       Impact factor: 4.033

3.  Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V.

Authors:  Hans Ulrichts; Miklós Udvardy; Peter J Lenting; Inge Pareyn; Nele Vandeputte; Karen Vanhoorelbeke; Hans Deckmyn
Journal:  J Biol Chem       Date:  2005-12-22       Impact factor: 5.157

4.  The dominant-negative von Willebrand factor gene deletion p.P1127_C1948delinsR: molecular mechanism and modulation.

Authors:  Caterina Casari; Mirko Pinotti; Stefano Lancellotti; Elena Adinolfi; Alessandra Casonato; Raimondo De Cristofaro; Francesco Bernardi
Journal:  Blood       Date:  2010-08-27       Impact factor: 22.113

5.  Highly reinforced structure of a C-terminal dimerization domain in von Willebrand factor.

Authors:  Yan-Feng Zhou; Timothy A Springer
Journal:  Blood       Date:  2014-01-06       Impact factor: 22.113

6.  Structure of the gene for human von Willebrand factor.

Authors:  D J Mancuso; E A Tuley; L A Westfield; N K Worrall; B B Shelton-Inloes; J M Sorace; Y G Alevy; J E Sadler
Journal:  J Biol Chem       Date:  1989-11-25       Impact factor: 5.157

7.  von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels.

Authors:  N Hickson; D Hampshire; P Winship; J Goudemand; R Schneppenheim; U Budde; G Castaman; F Rodeghiero; A B Federici; P James; I Peake; J Eikenboom; A Goodeve
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

8.  Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin.

Authors:  M F Hoylaerts; K Nuyts; K Peerlinck; H Deckmyn; J Vermylen
Journal:  Biochem J       Date:  1995-03-01       Impact factor: 3.857

9.  Globular structure of human ovulatory cervical mucus.

Authors:  Roberto Brunelli; Massimiliano Papi; Giuseppe Arcovito; Adriano Bompiani; Massimo Castagnola; Tiziana Parasassi; Beatrice Sampaolese; Federica Vincenzoni; Marco De Spirito
Journal:  FASEB J       Date:  2007-07-02       Impact factor: 5.191

10.  Ab initio modeling of small proteins by iterative TASSER simulations.

Authors:  Sitao Wu; Jeffrey Skolnick; Yang Zhang
Journal:  BMC Biol       Date:  2007-05-08       Impact factor: 7.431

View more
  1 in total

1.  The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms.

Authors:  Monica Sacco; Stefano Lancellotti; Alessio Branchini; Maira Tardugno; Maria Francesca Testa; Barbara Lunghi; Francesco Bernardi; Mirko Pinotti; Betti Giusti; Giancarlo Castaman; Raimondo De Cristofaro
Journal:  J Thromb Haemost       Date:  2022-06-09       Impact factor: 16.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.